SOURCE: Kalorama Information

Kalorama Information

January 19, 2012 11:38 ET

Growth of Vaccines Calls for Better, Faster Production

NEW YORK, NY--(Marketwire - Jan 19, 2012) - What a difference a decade has made in vaccines. According to a new market research report from healthcare publisher Kalorama Information, ten years ago the vaccine market was $5.7 billion dollars. Now, driven partially by the adult influenza vaccine market, and new brands such as Gardasil and Prevnar, the vaccine market has soared to over $27 billion. This kind of growth has strained vaccine production capacity and will drive new investment and innovation in this area. The firm published its findings in its recent report, Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts).

"It's an industry that needs to change production to match the demand," said Bruce Carlson, publisher of Kalorama Information. "The industry will continue to move from egg-based to cell-based, plant-based and insect-based production technologies."

Many adult and pediatric vaccines are produced by efficient cell-based technologies. Influenza uses a production system based on growing vaccines in chicken eggs, a technology that has been used since the middle of the last century. Novel vaccine production techniques are underway but the major technology is still egg-based. Flu vaccines are among the few that confer no long-term immunity and must be administered annually. A huge global effort is required each year by infectious disease monitoring organizations, biologics manufacturers, finish and fill suppliers, government regulatory agencies, distributors, and primary healthcare providers. These issues will become important, as production capacity is increasing. Kalorama indicates that the vaccine industry overall produced an estimated 23 billion doses in 2010, and demand should increase that number to 35 billion doses by 2015.

Kalorama also projects a small but growing opportunity for CMOs, contract manufacturing organizations who can help branded makers with clinical trial batches, new products where existing facilities won't cope, and increased pandemic demand.

"Quality control and tight regulation have made it so that, in most cases, vaccine companies do the manufacturing work themselves," said Carlson. "You don't see the outsourcing you do in other industries. However, there are some partnerships now and we expect more as makers cope with increased demand."

For more information, including estimates of industry vaccine production spending and profiles of vaccine makers and CMOs, see Kalorama's new report, Vaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts).

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact Information